Atour Lifestyle Holdings Limited announced a second 2026 cash dividend of $0.17 per ordinary share, or $0.51 per ADS, totaling about $69 million. Combined with the first 2026 dividend of $73 million, total dividends for the year reach approximately $142 million. This payout aligns with Atour's three-year policy to distribute at least 50% of net income annually. The dividend will be paid around December 9, 2026, to shareholders recorded by November 23, 2026.
Atour Lifestyle Holdings Limited's dividend announcement comes as a backdrop to the Consumer Cyclical sector's activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Nov 10, 2026 17:41 WIB: out of 134 priced US stocks, 71 rose and 54 fell. Among notable movers, VIPS traded at USD 13.86 with a 1-day gain of 1.24% and a typical hold time of 51 days, while TCOM and SE showed similar 1-day gains of 1.16% and 1.14%, respectively, with SE attracting a strong buy interest at 87% of Pluang order activity.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
